Latest News about REGN
Recent news which mentions REGN
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
From Benzinga
Market corrections are good buying opportunities, says Goldman Sachs — but only when this happens
January 31, 2022
From MarketWatch
A Deep Dive Into the Video Game Industry
January 29, 2022
From Motley Fool
Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?
January 29, 2022
From Motley Fool
From Benzinga
From Benzinga
From MarketWatch
Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments
January 25, 2022
From MarketWatch
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
January 25, 2022
From Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
From Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
January 24, 2022
From Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
From Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
From Benzinga
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
January 19, 2022
Tickers
REGN
From Benzinga
2 Top Biotech Stocks to Buy and Hold for 10 Years
January 17, 2022
From Motley Fool
3 Top Biotech Stocks to Buy Right Now
January 15, 2022
From Motley Fool
From Benzinga
From Benzinga
From Motley Fool
Why JPMorgan Is Among Rob Sechan's Top Picks For 2022
January 10, 2022
From Benzinga
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
January 05, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
From Benzinga
3 Healthcare Stocks That Could Rocket Higher in 2022
January 04, 2022
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
January 03, 2022
From Benzinga
Better Buy: CRISPR vs. Intellia
January 03, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
From Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
From Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
From Benzinga
2 No-Brainer Healthcare Stocks to Buy Right Now
December 13, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.